Evidence map›Paper›PMID 30042672›Full record

ReviewFrontiers in synaptic neuroscience2018

Brain Dopamine Transmission in Health and Parkinson's Disease: Modulation of Synaptic Transmission and Plasticity Through Volume Transmission and Dopamine Heteroreceptors.

Dasiel O Borroto-Escuela, Miguel Perez De La Mora, Paul Manger, Manuel Narváez, Sarah Beggiato, Minerva Crespo-Ramírez, Gemma Navarro, Karolina Wydra, Zaida Díaz-Cabiale, Alicia Rivera and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in synaptic neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. CaNeuroscience bulletin · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Behavioral encoding across timescales by region-specific dopamine dynamics.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Dopamine, Immunity, and Disease.Pharmacological reviews · 2023
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 7 countries.

Dasiel O Borroto-EscuelaDepartment of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Miguel Perez De La MoraInstituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Paul MangerFaculty of Health Sciences, School of Anatomical Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Manuel NarváezFacultad de Medicina, Instituto de Investigación Biomédica de Málaga, Málaga, Spain.
Sarah BeggiatoDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Minerva Crespo-RamírezInstituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Gemma NavarroDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biomedicine, University of Barcelona, Barcelona, Spain.
Karolina WydraLaboratory of Drug Addiction Pharmacology, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Zaida Díaz-CabialeFacultad de Medicina, Instituto de Investigación Biomédica de Málaga, Málaga, Spain.
Alicia RiveraDepartment of Cell Biology, Faculty of Sciences, University of Málaga, Málaga, Spain.
Luca FerraroDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Sergio TanganelliDepartment of Life Sciences and Biotechnology (SVEB), University of Ferrara, Ferrara, Italy.
Małgorzata FilipLaboratory of Drug Addiction Pharmacology, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Rafael FrancoDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biomedicine, University of Barcelona, Barcelona, Spain.
Kjell FuxeDepartment of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
University of Ferrara · ITInstituto de Investigación Biomédica de Málaga · ESKarolinska Institutet · SEUniversidad Nacional Autónoma de México · MXInstitute for Research in Biomedicine · ESMaj Institute of Pharmacology · PLPolish Academy of Sciences · PLUniversidad de Málaga · ESUniversitat de Barcelona · ESUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This perspective article provides observations supporting the view that nigro-striatal dopamine neurons and meso-limbic dopamine neurons mainly communicate through short distance volume transmission in the um range with dopamine diffusing into extrasynaptic and synaptic regions of glutamate and GABA synapses. Based on this communication it is discussed how volume transmission modulates synaptic glutamate transmission onto the D1R modulated direct and D2R modulated indirect GABA pathways of the dorsal striatum. Each nigro-striatal dopamine neuron was first calculated to form large numbers of neostriatal DA nerve terminals and then found to give rise to dense axonal arborizations spread over the neostriatum, from which dopamine is released. These neurons can through DA volume transmission directly influence not only the striatal GABA projection neurons but all the striatal cell types in parallel. It includes the GABA nerve cells forming the island-/striosome GABA pathway to the nigral dopamine cells, the striatal cholinergic interneurons and the striatal GABA interneurons. The dopamine modulation of the different striatal nerve cell types involves the five dopamine receptor subtypes, D1R to D5R receptors, and their formation of multiple extrasynaptic and synaptic dopamine homo and heteroreceptor complexes. These features of the nigro-striatal dopamine neuron to modulate in parallel the activity of practically all the striatal nerve cell types in the dorsal striatum, through the dopamine receptor complexes allows us to understand its unique and crucial fine-tuning of movements, which is lost in Parkinson's disease. Integration of striatal dopamine signals with other transmitter systems in the striatum mainly takes place via the receptor-receptor interactions in dopamine heteroreceptor complexes. Such molecular events also participate in the integration of volume transmission and synaptic transmission. Dopamine modulation of the glutamate synapses on the dorsal striato-pallidal GABA pathway involves D2R heteroreceptor complexes such as D2R-NMDAR, A2AR-D2R, and NTSR1-D2R heteroreceptor complexes. The dopamine modulation of glutamate synapses on the striato-entopeduncular/nigral pathway takes place mainly via D1R heteroreceptor complexes such as D1R-NMDAR, A2R-D1R, and D1R-D3R heteroreceptor complexes. Dopamine modulation of the island/striosome compartment of the dorsal striatum projecting to the nigral dopamine cells involve D4R-MOR heteroreceptor complexes. All these receptor-receptor interactions have relevance for Parkinson's disease and its treatment.

Indexed as

dopamine receptorG protein-coupled receptorheteroreceptor complexesneural plasticityoligomerizationParkinson's diseasesvolume transmission

Identifiers

PMID30042672
PMCPMC6048293
OpenAlexW2815732303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.